- Home
- KPRX vs GIPR Comparison
KPRX vs GIPR Comparison
Compare KPRX & GIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPRX | GIPR |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 6.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KPRX | GIPR |
|---|---|---|
| Price | $2.13 | $0.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 77.1K | 56.8K |
| Earning Date | 03-24-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $9,953,920.00 |
| Revenue This Year | N/A | $1.12 |
| Revenue Next Year | N/A | $0.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.77 | $0.63 |
| 52 Week High | $4.18 | $2.06 |
Technical Indicators
Market Signals| Indicator | KPRX | GIPR |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 39.12 |
| Support Level | $2.15 | $0.65 |
| Resistance Level | $2.45 | $0.70 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 25.58 | 1.80 |
Price Performance
Historical ComparisonAbout KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.